Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate receptor during experimental encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit by Knegt, R.J. (Robert) de et al.
Metabolic Brain Disease, Vol. 8, No. 2, 1993 
Binding of the Ligand [3H]MK-801 to the MK-801 Binding 
Site of the N-Methyl-D-Aspartate Receptor During 
Experimental Encephalopathy from Acute Liver Failure and 
from Acute Hyperammonemia n the Rabbit. 
R.J. de Knegt 1, J. Kornhuber 2, S.W. Schalm 1, K. Rusche 2, P. Riederer 2 and J. Tan 3 
Received November 19,1992; accepted December 281992 
Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate 
(NMDA) receptor population on brain homogenates in rabbits was studied during 
experimental encephalopathy from acute liver failure and from acute hyperammonemia in 
the rabbit. Homogenates were prepared from brain cortex, hippocampus and striatum. 
Hepatic encephalopathy was induced by a two-stage liver devascularization procedure and 
acute hyperammonemia by a prolonged ammonium-acetate infusion; rabbits receiving a 
sodium-potassium-acetate infusion served as controls. In these animal models extracellular 
brain glutamate l vels are known to be elevated. However no significant alterations in the 
number nor the affinity of the MK-801 binding sites of the NMDA receptors were found 
during acute liver failure and acute hyperammonemia. These findings suggest hat the 
NMDA receptor population remains unaltered in experimental encephalopathy from acute 
liver failure and acute hyperammonemia, despite alterations in extracellular brain glutamate 
levels. 
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INTRODUCTION 
Hepatic encephalopathy is a neuropsychiatric syndrome caused by serious liver disease. 
Hyperammonemia is thought o be an important causative factor since plasma mmonia 
levels often correlate with the degree of encephalopathy (Stahl, 1963), administration of 
ammonium-salts to patients with chronic liver disease provokes encephalopathy (Phillips et 
al., 1952) and lowering of plasma ammonia by lactulose therapy often improves 
encephalopathy (Bircher et al., 1971). Furthermore proliferation of astrocytes, the 
morphological substrate of chronic hepatic encephalopathy, is also found in patients with 
the congenital hyperammonemia syndromes (Norenberg et al., 1985). However, the exact 
mechanism how hyperammonemia contributes to the syndrome of hepatic encephalopathy 
remains to be elucidated. 
One of the current opinions with regard to the pathogenesis ofhepatic encephalopathy 
is a dysbalance between euro-inhibition and neuro-excitation (Schenker, 1989). Several 
groups have proposed that neuro-inhibition via GABA or endogenous benzodiazepines is 
enhanced; we are investigating whether excitatory neurotransmission, especially glutamate 
neurotransmission, is diminished uring hepatic encephalopathy. A large portion of central 
mammalian eurons use the amino acid glutamate as an excitatory neurotransmitter 
(Fonnum, 1984), and the metabolism ofglutamate isrelated closely to ammonia metabolism 
(Cooper and Plum, 1987). In vitro and in vivo experiments have shown that both liver failure 
and hyperammonemia m y alter brain glutamate homeostasis. Whole brain glutamate 
contents were found to be diminished uring hepatic encephalopathy or hyperammonemia 
in patients as well as animals (Hindfelt et al., 1977; Watanabe t al., 1985; Lavoie et al., 
1987; Bosman et al., 1990; Swain et al., 1992). Recently, using in vivo brain dialysis, we 
have demonstrated increased extracellular glutamate levels in the brains of rabbits 
developing encephalopathy from acute ischemic liver failure or acute hyperammonemia (De 
Knegt et al., 1993a). The finding of increased extracellular glutamate concentrations 
indicates increased glutamate availability in the synaptic cleft, i.e. increased glutamate 
exposure at the receptor level, during hepatic encephalopathy and hyperammonemia. 
Increased glutamate concentrations in the cerebrospinal f uid of patients with hepatic 
encephalopathy suggest that increased glutamate exposure also occurs clinically (Van Sande 
et al., 1970; Vergara et al., 1974; Watanabe t al., 1984). To explain the paradoxical 
observation ofincreased excitatory neurotransmitter molecules ina state of neuroinhibition, 
the following hypothesis was constructed. Initially, increased glutamate levels lead to 
increased excitation; thereafter prolonged activation of glutamate receptors leads to a 
compensatory down-regulation (Mukherjee t al., 1985), which in turn impairs glutamate 
neurotransmission. 
To determine whether the hepatic encephalopathy observed in our animal models is 
associated with changes in the glutamate r ceptors, we performed binding studies in brains 
from rabbits developing encephalopathy from acute liver failure or acute hyperammonemia. 
As the N-methyl-D-aspartate (NMDA) receptor isthe best characterized ofthe acidic amino 
acid receptor subtypes (Fagg et al., 1991), we measured the binding of [3H]MK-801 -a 
specific ligand of the NMDA receptor- to homogenates prepared from different regions from 
the brains of normal rabbits and rabbits with encephalopathy due to acute ischemic liver 
failure or acute hyperammonemia. 
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METHODS 
Animals 
18 (3 groups of 6) New Zealand white rabbits weighing 2-3 kg were used. 
Animal models 
Acute liver failure was induced by a two-stage liver devascularization procedure as 
described earlier (Fick et al., 1987; Fick et al., 1989). Under anesthesia a laparotomy was 
performed: a loose ligature was placed around the hepatoduodenal ligament and guided 
through a plastic tube through the abdominal wall to the subcutaneous layer of the left 
subcostal region, and a small-diameter (5 mm) side-to-side portacaval shunt was constructed. 
During this procedure the superior mesenteric artery was clamped to reduce splanchnic blood 
stasis. To correct acidosis after elease of the vascular clamps 5 ml 8.4% sodium bicarbonate 
were given intravenously. Postoperatively the rabbits were given 50 ml 10% glucose 
subcutaneously, followed by standard laboratory chow and water ad libitum. The second 
day after the operation acute ischemic liver failure was induced by tightening the loose 
ligature around the hepatoduodenal ligament after giving 50 mg amoxicillin intravenously. 
The rabbits were subsequently placed in a restraining box. To prevent hypoglycemia 10% 
glucose was given intravenously, starting at a rate of 3 ml/hr and which was adjusted 
according to the plasma glucose level when necessary. 
Acute hyperammonemia wasinduced by a prolonged intravenous ammonium-acetate 
(NH4Ac) infusion as described earlier (Fick et al., 1989). After insertion ofa Venflon cannula 
(diameter 0.8 mm, Viggo, Helsingborg, Sweden) into an ear vein, NHaAc was infused at a 
constant rate of 6 ml/hr, starting with an initial dose of 0.8 mmol/kg/hr, which was 
subsequently increased by 0.2 mmol/kg/hr every two hours. 
Control rabbits received a sodium/potassium acetate (NaKAc) solution, which was 
infused -as far as the acetate concentration was concerned- as in the NH4Ac experiments. 
Laboratory measurements 
Arterial blood samples were taken from all rabbits tudied at 0,1 and 2 hours, and every 
two hours thereafter for ammonia determination, using an enzymatic method (Da 
Fonseca-Wolheim, 1973). Blood glucose levels were measured hourly (Haemoglucotest, 
Boehringer, Germany). 
Clinical signs of encephalopathy 
During study all rabbits were kept in a restraining box. However, at regular 
time-intervals the rabbits were put into a large cage for clinical evaluation. Clinical signs 
studied were spontaneous activity, body posture, fighting reflex, presence of ataxia and 
reaction to a painful stimulus. In most rabbits with acute hepatic encephatopathy due to 
ischemic liver cell necrosis two stages of hepatic encephalopathy are easily recognizable 
(Van der Rijt et al., 1990). Stage A is characterized bya disturbed righting reflex: the animal 
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will not get up immediately when placed on its side. At stage B the rabbit lies in the cage 
and cannot achieve the sitting position, even after stimulation, and usually cannot lift its 
head. All rabbits with ischemic liver cell necrosis and all rabbits receiving NH4Ac were 
sacrificed uring encephalopathy stage B. The rabbits receiving NaKAc were sacrificed at 
the same time as the rabbits receiving NHnAc. All animals were sacrificed by decapitation. 
[3H]MK-801 binding to the MK-801 binding site of the NMDA receptor 
Within 10 minutes after decapitation the brain was removed and hippocampus, frontal 
cortex and striatum were dissected. Tissue samples were sealed in vacuum plastic bags and 
stored at -70~ until fmrther analysis. The binding of [3H]MK-801 to the MK-801 binding 
site of the NMDA receptor was studied as described earlier (Wong et al., 1988, Kornhuber 
et al., 1989a, Kornhuber et al., 1989b). Rabbit brain tissue was homogenized in about 50 
volumes of buffer with a glass-teflon homogenizer (at 2~ 5 mM Tris-HCl buffer, pH7.4; 
Potter S. Braun, FRG). The homogenate was pelleted (15000 xg, 20 min), resuspended by
vortexing and pelleted again. Then the homogenate was pelleted (40000 x g, 20 min) and 
resuspended 4 times in buffer. The protein concentration was measured in the final 
homogenate with bovine gamma-globulin as standard (Bradford, 1976). Binding 
experiments were carded out at 21~ in plastic microtitre plates in a total volume of 0.22 
ml. First, in hippocampus, cerebral cortex and striatum a one-point-binding assay was 
performed for which the incubation medium consisted of 0.22 ml 5 mM Tris-HCL (pH 7.4) 
containing 3nM [3I-I]MK-801, 5 mM L-glutamate, 5 mM glycine, 10 mM MgCI2. Second, 
in the cerebral cortex saturation studies were performed for which 0.2-80 nM [3H]MK-801 
was used. After incubation for 22 hours bound ligand was separated from free ligand by 
rapid filtration through Whatman GF/B filters with a Titertek cell harvester followed by a 
10 second wash with cold assay buffer (4~ et al., 1988). The filters were transferred 
into plastic vials, 5 ml of a toluene-based scintillation cocktail was added (Rotiszint 22) and 
they were monitored for tritium in a Beckman LS 1801 counter at about 54% efficiency. 
Non-specific binding was defined as that not displaced by 100 mM of unlabelled MK-801. 
Final estimates of binding parameters were determined with a computerized, non-linear, 
least squares regression analysis (Munson and Rodbard, 1980). 
Because xperimental cute liver failure and acute hyperammonemia are known to 
increase brain water content by about ca. 2% (Swain et al., 1991; De Knegt et al., 1993b), 
calculation was based on pmol/mg protein unit. Such calculation ispractically independent 
of the presence of cerebral edema, as opposed to a calculation based on tissue weight. 
Necropsy 
After sacrifice of the animal necropsy was performed to exclude gross pathological 
abnormalities. In the animals with acute ischemic liver cell necrosis the liver was examined 
carefully to confirm tightening of the ligature. 
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Statistics 
All results are presented as mean + S.E.M. For statistical nalysis the unpaired Student' s 
t test when comparing two groups and the Student-Newman-Keuls te t when comparing 
three groups were applied. Statistical significance denotes p<0.05. 
All experiments were approved by the Ethical Committee on Animal Research of the 
Erasmus University Rotterdam. 
RESULTS 
Clinical signs of encephalopathy 
Encephalopathy from acute liver failure was characterized by complete loss of 
spontaneous activity, impaired body posture, absence of the righting reflex, decreased 
muscle tone and a diminished reaction to a painful stimulus. Rabbits with encephalopathy 
from acute hyperammonemia exhibited similar symptoms, but in addition had severe ataxia. 
All animals with acute liver failure and acute hyperammonemia developed encephalopathy 
stage B, after 14.8+0.2 and 15.5+1.9 hours respectively (meanY.+SEM, n=6). Two rabbits 
with acute liver failure died just before decapitation. Control studies were performed for 
14.7+1.8 hours (mear~+SEM, n=6); among the control rabbits no spontaneous deaths 
occurred. 
Plasma ammonia levels 
During the experiments increases of arterial ammonia levels in the rabbits with acute 
liver failure and acute hyperammonemia showed a similar pattern. At the start of the 
experiments ammonia levels tended to be higher in rabbits with acute liver failure (44+7 
mmol/l), due to their portacaval shunt, when compared to rabbits with acute 
hyperammonemia (9+3 mmol/1) or controls (33+10 mmol/1)(all three groups: mean!SEM, 
n=6). However, the difference did not reach statistical significance (p>0.05). During the 
experiments mean arterial ammonia levels tended to be higher among the rabbits receiving 
an ammonia infusion, but differences were not statistically different (table I). During 
encephalopathy stage B the difference inplasma mmonia levels between rabbits with acute 
liver failure (533+62 mmol/1) and rabbits with acute hyperammonemia (955+120 retool/l) 
reached statistical significance (p<0.05, mean+SEM, n=6)(table I).
[3H]MK-801 binding to the MK-801 binding site of the NMDA receptor 
Homogenates were prepared from the hippocampus, cerebral cortex and striatum as 
these are major anatomic regions in which glutamate is used for neurotransmission. In 
control rabbits [3H]MK-801 binding to synaptical membranes in the one-point assay was 
high in the hippocampus, intermediate in the cortex and low in the striatum. No significant 
differences in [3H]MK-801 binding were found in rabbits exhibiting severe ncephalopathy 
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stage B from acute liver failure or acute hyperammonemia (Table II). The single 
concentration of [3H]MK-801 (3 nM) labels primarily the high affinity binding site (about 
80%) compared to the low-affinity binding site (about 20%)(see below). 
Saturation studies of the binding of [3I-I]MK-801 to homogenates from cerebral cortex 
demonstrated two different binding sites, one with low and one with high affinity. Compared 
to corresponding data for controls, the values for KD and Bmax were not changed in rabbits 
with encephalopathy from acute liver failure or acute hyperammonemia (t ble III). 
DISCUSSION 
The results of the present study indicate there are no significant alterations inthe NMDA 
receptor population i  cerebral cortex -and probably also in hippocampus and striatum- of 
rabbits with severe ncephalopathy from acute liver failure or acute hyperammonemia. 
In this study heterogeneity of [3H]MK-801 binding sites was found, as reported recently 
by several other groups (Quarum et al., 1990, Steele et al., 1991). As discussed before 
(Kornhuber et al., 1989b), the high affinity binding sites as found with the present technique 
may be identical to those found previously in rat brain (Wong et al., 1988). The exact nature 
of the low-affinity binding site is not clear at present. However, it has been proposed that 
[3H]MK-801 labels an additional binding site, for instance the nicotinic receptor channel 
(CaUachan et al., 1988, Kavanaugh et al., 1989, Ramoa et al., 1990, mad Amador et al., 
1991). With increasing ligand concentrations in saturation experiments, the amount of 
specific binding is decreasing from about 75% to 40% (Kornhuber et al., 1989a nd b). With 
such low specific binding it is not possible to determine the Kd and Bmax values of the 
low-affinity binding site (Kd2 and Bmax2) with high precision. This may explain the scatter 
of the Kd2 and Bmax2 values. 
Results of previous tudies reported on glutamate receptors in experimental hepatic 
encephalopathy ave been conflicting (table IV)(Rao et al., 1992). In rabbits with 
galactosamine induced acute liver failure [3H]glutamate binding was diminished (Ferenci 
et al., 1984a), which was subsequently shown to be the result of a decreased number of 
kainate receptors (Ferenci et al., 1984b). However, in acute liver failure from hepatectomy 
and tetrachloride in the rat (Watanabe t al., 1988), thioacetamide in the rat (Zimmermann 
et al., 1989) and ischemic liver necrosis in the rabbit (present study) no changes were found, 
although in the latter we cannot exclude changes of the kainate and AMPA receptors. In rats 
with chronic hepatic encephalopathy glutamate binding to the NMDA receptor was 
diminished (Peterson et al., 1990); in dogs with chronic hepatic encephalopathy NMDA 
receptor binding appeared normal whereas changes occurred in the kainate and AMPA 
receptors (Maddison et al., 1991). No changes in glutamate receptors were found in models 
of acute hyperammonemia in rabbits (Ferenci et al., 1984a, present study). However, the 
number of all three subgroups of glutamate receptors were found to be diminished in 
hyperammonemic rats (Rao et al., 1991). Thus, during experimental hepatic encephalopathy 
from acute liver failure there may be a selective loss of kainate receptors (Ferenci et al., 
1984a), with a preservation of NMDA receptors (present study). Chronic hepatic 
encephalopathy appears to be associated with variable changes of the glutamate receptor 
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populations (Peterson et al., 1990; Maddison et al., 1991). Conflicting results have also been 
found during hyperammonemia (Ferenci et al., 1984a; Rao et al., 1991; and present study). 
Experimental cute hepatic encephalopathy and acute hyperammonemia appear to be 
associated with increased extracellular glutamate l vels (Moroni et al., 1983; Hamberger 
and Nystrom, 1984; De Knegt et al., 1993a). Increased glutamate concentrations in the 
cerebrospinal f uid of patients with hepatic encephalopathy suggest hat increased 
extracellular b ain glutamate also occurs clinically (Van Sande et al., 1970; Vergara et al., 
1974; Watanabe t al., 1984). Increased extracellular glutamate together with a normal 
NMDA receptor population, might lead to glutamate overexposure. In brain ischemia nd 
epilepsy there is evidence indicating that prolonged glutamate exposure isdeleterious tothe 
brain (Engelsen, 1986). In these conditions most toxic effects of glutamate are thought to 
result from a prolonged epolarizing action at the postsynaptic receptor sites (Rothman and 
Olney, 1986; Rothman and Olney, 1987), in particular the NMDA receptor sites (Fagg and 
Massieu, 1991). This action is assumed to give rise to membrane p rmeability changes which 
lead to impaired ion homeostasis (Rothman and Olney, 1986; Rothman and Olney, 1987). 
Especially increased neuronal calcium influx may be responsible for cell swelling and 
degeneration (Collins et al., 1989). Maybe this mechanism is also of importance in 
encephalopathy from acute liver failure and acute hyperammonemia. 
In conclusion, the NMDA receptor population is normal during encephalopathy from 
acute liver failure and acute hyperammonemia in the rabbit. In addition, as there is 
experimental evidence of increased extracellular b ain glutamate concentrations i  these 
conditions, the concept of glutamate overexposure should receive further attention i studies 
on the pathogenesis of hepatic encephalopathy. 
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